Friday, March 15, 2019
Flow Pharma , focused on developing personalized cancer vaccines as a biotechnology company in the San Francisco Bay area, is today the ONCO biotech company in Norway Announced collaboration with immunity .
Under this Agreement, onco immunity is Immuneoprofiler ™ software flow Pharma licensed to, FlowVax platform to support the clinical development and commercialization of products based on. ImmuneoprofilerTM has recently acquired CE-IVD certification as a medical device, and eliminates some of the important unresolved issues in neonatal antigen prediction. The FlowVax vaccine platform, developed by Flow Pharma, is optimized to simultaneously provide multiple nascent antigen peptide targets to enhance tumor-specific killer T cell attack. Oncoy Community will develop a customized machine learning layer using the clinical data generated by Flow Pharma . It works in conjunction with the ImmuenceoprofilerTM software to make predictions compatible with the FlowVax platform.
"Octocoy's CEO , Richard Stratford , said: "This wonderful partnership / licensing agreement provides a great opportunity for Oncoy Community to apply its ImmuneoprofilerTM prediction software to FlowVax technology in clinical conditions. Oncoy Community is a specialist in immunoinformatics expertise and machine learning. You also have the opportunity to leverage the power to develop customized solutions for the FlowVax platform to support the current and future needs of Flow Pharma. "
Flow Pharma's CEO Reedshammen (MD) stated: "We believe that OnCoimunity's ImmuneoprofilerTM software is the best-in-class solution for predicting clinically relevant and authentic neonatal antigens. The Flow Pharma's bioinformatics team works closely with OnCoymunity. We will work together to customize the use of ImmuneoprofilerTM and optimize the use of the data we will generate. ”